Are Orphan Drugs Still a Licence to Print Money?
Hosted By : Andrea CharlesJuly 21, 2011
Rate this Podcast:
(0.0 Stars | 1 Vote)
About this Podcast...
In this podcast Donald Macarthur, global pharmaceutical business analyst, speaks to Andrea Charles from Pharma IQ, about Pharma's steps into the orphan drug market and whether payers can afford to fund orphan drugs at a time of austerity measures. Macarthur also shares his insights on how reimbursement rules have affected the market and how risk sharing schemes and patient registries can help bridge the data gap.
Rate this Podcast:
(0.0 Stars | 1 Vote)
Events of Interest
-
Global HTA and CER Forum 2011
August 31, 2011
Register Now -
Global Formulation and Drug Delivery Summit 2012
Park Hotel Amsterdam, Netherlands
April 16- 18, 2012 -
4th Clinical Trials Supply & Logistics Summit
San Francisco, CA
June 25- 27, 2012 -
EU Product Launch – Key Considerations for Successful Niche and Orphan Drug Product Launches
February 9, 2012
Register Now






Not a member? Sign Up
Reasons for Joining
Address your challenges through knowledge sharing with peers from our global network of specialists.
Benchmark your business initiatives with the who's who in the field.
Hear from industry pioneers how to maximize ROI in today's challenging economy.
And best of all It's FREE!